Compare DTM & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | DTM | ABVX |
|---|---|---|
| Founded | 2021 | 2013 |
| Country | United States | France |
| Employees | N/A | 67 |
| Industry | Oil & Gas Production | |
| Sector | Utilities | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8B | 10.5B |
| IPO Year | 2021 | N/A |
| Metric | DTM | ABVX |
|---|---|---|
| Price | $142.21 | $116.35 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 12 |
| Target Price | ★ $134.80 | $128.42 |
| AVG Volume (30 Days) | ★ 812.0K | 724.1K |
| Earning Date | 05-22-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.47% | N/A |
| EPS Growth | ★ 19.44 | N/A |
| EPS | ★ 4.30 | N/A |
| Revenue | ★ $1,243,000,000.00 | N/A |
| Revenue This Year | $9.25 | N/A |
| Revenue Next Year | $7.51 | $0.22 |
| P/E Ratio | $33.02 | ★ N/A |
| Revenue Growth | ★ 26.71 | N/A |
| 52 Week Low | $83.30 | $4.77 |
| 52 Week High | $142.85 | $148.83 |
| Indicator | DTM | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 79.25 | 45.08 |
| Support Level | $102.20 | $107.99 |
| Resistance Level | N/A | $131.27 |
| Average True Range (ATR) | 3.65 | 5.01 |
| MACD | 0.44 | -1.39 |
| Stochastic Oscillator | 95.09 | 39.63 |
DT Midstream Inc is an owner, operator, and developer of natural gas midstream interstate and intrastate pipelines; storage and gathering systems; and compression, treatment, and surface facilities. It provides multiple, integrated natural gas services to customers through interstate pipelines, intrastate pipelines, storage systems, lateral pipelines and related treatment plants and compression and surface facilities, and gathering systems and related treatment plants and compression and surface facilities. The segments of the group are Pipeline and Gathering. It generates revenue from pipeline, storage, and gathering systems, substantially all of which are located in the Midwestern U.S., Eastern Canada, Northeastern U.S., and Gulf Coast regions.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.